C4 Therapeutics, Inc. (NASDAQ: CCCC) is a Healthcare company (Biotechnology) with a market capitalization of $332M. The Maz Rating grades it against the other companies in its sector.
C4 Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.53, C4 Therapeutics, Inc. trades at 10.2x sales and 1.5x book value. Over the last twelve months it generated about $33M of revenue and a net loss of $95M. It runs a gross margin of 94.4%, an operating margin of -315.9% and a net margin of -282.2%. It shows return on equity of -37.7%, return on invested capital of -34.3% and a free cash flow yield of -24.1%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 5.17. Over the past 52 weeks the share price ranged from $1.69 to $5.17, with a beta of 3.16.
C4 Therapeutics, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 11 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, C4 Therapeutics, Inc. (CCCC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 63.2% / 30% · Interest income / Revenue 32.5% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 47.2% / 33% · Receivables / Mkt Cap (36m) 0.32% / 49% · Interest income / Revenue 32.5% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 47.2% / 33.33% · Receivables / Mkt Cap (24m) 0.32% / 33.33% · Interest income / Revenue 32.5% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.47% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 68.4% / 33.33% · Receivables / Avg Assets (4Q) 0.58% / 33.33% · Interest income / Revenue 32.5% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 61.9% / 33.33% · (Cash+Recv) / Total Assets 62.3% / 33.33% · Interest income / Revenue 32.5% / 5% | Fail |
No. As of September 2026, C4 Therapeutics, Inc. (CCCC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. C4 Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 32.5% of each dividend: C4 Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.